Renovaro Biosciences Inc (RENB) — Cash Flow-to-Debt Ratio
Renovaro Biosciences Inc (RENB) has a Cash Flow-to-Debt Ratio of -0.06x as of June 2025, meaning its operating cash flow of $-1.81 Million could theoretically repay 0% of its total liabilities ($29.58 Million) in one year. See working capital to net assets of Renovaro Biosciences Inc to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Renovaro Biosciences Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Renovaro Biosciences Inc across 14 annual periods. Also explore Renovaro Biosciences Inc net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Renovaro Biosciences Inc (2012–2025)
Year-by-year debt coverage analysis for Renovaro Biosciences Inc. For market capitalisation and broader financial context, see RENB market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.35x | $-10.97 Million | $31.15 Million | ▲ +0.0% |
| 2024 | -0.35x | $-10.97 Million | $31.15 Million | ▲ +64.7% |
| 2023 | -1.00x | $-11.77 Million | $11.80 Million | ▲ +23.8% |
| 2022 | -1.31x | $-15.73 Million | $12.01 Million | ▲ +5.1% |
| 2021 | -1.38x | $-20.61 Million | $14.94 Million | ▼ -56.0% |
| 2020 | -0.88x | $-10.46 Million | $11.83 Million | ▲ +29.6% |
| 2019 | -1.26x | $-8.51 Million | $6.78 Million | ▼ -587.6% |
| 2018 | -0.18x | $-4.34 Million | $23.76 Million | ▲ +53.7% |
| 2017 | -0.39x | $-1.18 Million | $2.99 Million | ▲ +59.7% |
| 2016 | -0.98x | $-1.47 Million | $1.51 Million | ▲ +15.7% |
| 2015 | -1.16x | $-2.03 Million | $1.76 Million | ▼ -14.1% |
| 2014 | -1.01x | $-2.13 Million | $2.10 Million | ▼ -140.1% |
| 2013 | -0.42x | $-30.09K | $71.23K | ▲ +53.9% |
| 2012 | -0.92x | $-24.95K | $27.23K | — |